Literature DB >> 22683134

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.

Leigh Perreault1, Qing Pan, Kieren J Mather, Karol E Watson, Richard F Hamman, Steven E Kahn.   

Abstract

BACKGROUND: Our objective was to quantify and predict diabetes risk reduction during the Diabetes Prevention Program Outcomes Study (DPPOS) in participants who returned to normal glucose regulation at least once during the Diabetes Prevention Program (DPP) compared with those who consistently met criteria for prediabetes.
METHODS: DPPOS is an ongoing observational study of participants from the DPP randomised trial. For this analysis, diabetes cumulative incidence in DPPOS was calculated for participants with normal glucose regulation or prediabetes status during DPP with and without stratification by previous randomised treatment group. Cox proportional hazards modelling and generalised linear mixed models were used to quantify the effect of previous (DPP) glycaemic status on risk of later (DPPOS) diabetes and normal glucose regulation status, respectively, per SD in change. Included in this analysis were 1990 participants of DPPOS who had been randomly assigned to treatment groups during DPP (736 intensive lifestyle intervention, 647 metformin, 607 placebo). These studies are registered at ClinicalTrials.gov, NCT00004992 (DPP) and NCT00038727 (DPPOS).
FINDINGS: Diabetes risk during DPPOS was 56% lower for participants who had returned to normal glucose regulation versus those who consistently had prediabetes (hazard ratio [HR] 0·44, 95% CI 0·37-0·55, p<0·0001) and was unaffected by previous group assignment (interaction test for normal glucose regulation and lifestyle intervention, p=0·1722; normal glucose regulation and metformin, p=0·3304). Many, but not all, of the variables that increased diabetes risk were inversely associated with the chance of a participant reaching normal glucose regulation status in DPPOS. Specifically, previous achievement of normal glucose regulation (odds ratio [OR] 3·18, 95% CI 2·71-3·72, p<0·0001), increased β-cell function (OR 1·28; 95% CI 1·18-1·39, p<0·0001), and insulin sensitivity (OR 1·16, 95% CI 1·08-1·25, p<0·0001) were associated with normal glucose regulation in DPPOS, whereas the opposite was true for prediction of diabetes, with increased β-cell function (HR 0·80, 95% CI 0·71-0·89, p<0·0001) and insulin sensitivity (HR 0·83, 95% CI 0·74-0·94, p=0·0001) having a protective effect. Among participants who did not return to normal glucose regulation in DPP, those assigned to the intensive lifestyle intervention had a higher diabetes risk (HR 1·31, 95% CI 1·03-1·68, p=0·0304) and lower chance of normal glucose regulation (OR 0·59, 95% CI 0·42-0·82, p=0·0014) than did the placebo group in DPPOS.
INTERPRETATION: We conclude that prediabetes is a high-risk state for diabetes, especially in patients who remain with prediabetes despite intensive lifestyle intervention. Reversion to normal glucose regulation, even if transient, is associated with a significantly reduced risk of future diabetes independent of previous treatment group. FUNDING: US National Institutes of Health.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683134      PMCID: PMC3555407          DOI: 10.1016/S0140-6736(12)60525-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group.

Authors: 
Journal:  Diabetes Care       Date:  2000-11       Impact factor: 19.112

2.  Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study.

Authors:  F de Vegt; J M Dekker; A Jager; E Hienkens; P J Kostense; C D Stehouwer; G Nijpels; L M Bouter; R J Heine
Journal:  JAMA       Date:  2001-04-25       Impact factor: 56.272

3.  Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial.

Authors:  Toshikazu Saito; Makoto Watanabe; Junko Nishida; Tomono Izumi; Masao Omura; Toshikazu Takagi; Ryuzo Fukunaga; Yasutsugu Bandai; Naoko Tajima; Yosikazu Nakamura; Masaharu Ito
Journal:  Arch Intern Med       Date:  2011-08-08

4.  Pioglitazone for diabetes prevention in impaired glucose tolerance.

Authors:  Ralph A DeFronzo; Devjit Tripathy; Dawn C Schwenke; MaryAnn Banerji; George A Bray; Thomas A Buchanan; Stephen C Clement; Robert R Henry; Howard N Hodis; Abbas E Kitabchi; Wendy J Mack; Sunder Mudaliar; Robert E Ratner; Ken Williams; Frankie B Stentz; Nicolas Musi; Peter D Reaven
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

6.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

7.  The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging.

Authors:  James B Meigs; Denis C Muller; David M Nathan; Deirdre R Blake; Reubin Andres
Journal:  Diabetes       Date:  2003-06       Impact factor: 9.461

8.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

9.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Authors:  Jarl S Torgerson; Jonathan Hauptman; Mark N Boldrin; Lars Sjöström
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

10.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.

Authors:  Thomas A Buchanan; Anny H Xiang; Ruth K Peters; Siri L Kjos; Aura Marroquin; Jose Goico; Cesar Ochoa; Sylvia Tan; Kathleen Berkowitz; Howard N Hodis; Stanley P Azen
Journal:  Diabetes       Date:  2002-09       Impact factor: 9.461

View more
  159 in total

Review 1.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

2.  A feasibility study to develop a diabetes prevention program for young adults with prediabetes by using digital platforms and a handheld device.

Authors:  EunSeok Cha; Kevin H Kim; Guillermo Umpierrez; Colleen R Dawkins; Morenike K Bello; Hannah M Lerner; K M Venkat Narayan; Sandra B Dunbar
Journal:  Diabetes Educ       Date:  2014-06-20       Impact factor: 2.140

Review 3.  Exercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism.

Authors:  Steven K Malin; Zhenqi Liu; Eugene J Barrett; Arthur Weltman
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

4.  Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.

Authors:  Katherine A Pratte; Ann Johnson; Janette Beals; Ann Bullock; Spero M Manson; Luohua Jiang
Journal:  Diabetes Care       Date:  2019-06-08       Impact factor: 19.112

5.  A novel fasting blood test for insulin resistance and prediabetes.

Authors:  Jeff Cobb; Walter Gall; Klaus-Peter Adam; Pamela Nakhle; Eric Button; James Hathorn; Kay Lawton; Michael Milburn; Regis Perichon; Matthew Mitchell; Andrea Natali; Ele Ferrannini
Journal:  J Diabetes Sci Technol       Date:  2013-01-01

Review 6.  From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.

Authors:  Ofri Mosenzon; Stefano Del Prato; Meir Schechter; Lawrence A Leiter; Antonio Ceriello; Ralph A DeFronzo; Itamar Raz
Journal:  Cardiovasc Diabetol       Date:  2021-04-28       Impact factor: 9.951

7.  Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.

Authors:  Sun H Kim; Alice Liu; Danit Ariel; Fahim Abbasi; Cindy Lamendola; Kaylene Grove; Vanessa Tomasso; Gerald Reaven
Journal:  Diabetologia       Date:  2013-12-11       Impact factor: 10.122

Review 8.  The Case for Diabetes Population Health Improvement: Evidence-Based Programming for Population Outcomes in Diabetes.

Authors:  Sherita Hill Golden; Nisa Maruthur; Nestoras Mathioudakis; Elias Spanakis; Daniel Rubin; Mihail Zilbermint; Felicia Hill-Briggs
Journal:  Curr Diab Rep       Date:  2017-07       Impact factor: 4.810

9.  Prevention of Diabetes: Countless Opportunities and Clear Challenges.

Authors:  Anoop Misra
Journal:  Am J Lifestyle Med       Date:  2017-10-26

Review 10.  Long-term Sustainability of Diabetes Prevention Approaches: A Systematic Review and Meta-analysis of Randomized Clinical Trials.

Authors:  J Sonya Haw; Karla I Galaviz; Audrey N Straus; Alysse J Kowalski; Matthew J Magee; Mary Beth Weber; Jingkai Wei; K M Venkat Narayan; Mohammed K Ali
Journal:  JAMA Intern Med       Date:  2017-12-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.